Amino Acid Deficiency Secondary to Continuous Venovenous Hemofiltration in Acute Decompensation of Organic Acidemias: An Anabolic Dead End?
Abstract
OBJECTIVE: To evaluate the impact of continuous renal replacement therapy (CRRT) on plasma amino acid (AA) concentrations in patients with acute metabolic decompensation of organic acidemias (OAs), and to explore whether AA supplementation during CRRT may mitigate AA depletion. DESIGN: Multicenter retrospective observational study. SETTING: PICUs managing acute metabolic decompensations of OAs. PATIENTS OR SUBJECTS: Patients with confirmed OAs who underwent CRRT for severe acute metabolic decompensation. INTERVENTIONS: CRRT was initiated according to current guidelines in cases of severe decompensation. Standard metabolic management included high caloric intake through carbohydrates and lipids with temporary protein withdrawal (24-48 hr). In one patient, AA supplementation (2 g/kg) during CRRT combined with thiamin and citrate (anaplerotic therapy) was administered. MEASUREMENTS AND MAIN RESULTS: Plasma AA concentrations were measured before and after CRRT in nine patients with a median age of 21 days (interquartile range [IQR], 3-570 d). Quantitative variables are expressed as medians (IQR, 25th-75th). Before CRRT, 31% (95% CI, 24-39) of plasma AAs were below the normal range compared with 69% (95% CI, 59-77) after CRRT (p < 0.0001). A significant increase in lactatemia was observed following CRRT, without evidence of organ failure: median 2.2 mmol/L (IQR, 1.3-2.3) before CRRT vs. 5.3 mmol/L (IQR, 3.2-7.1) after CRRT; Hodges-Lehmann median difference +3.2 (95% CI, 0.8-5.6; p = 0.0065). In the patient receiving AA supplementation with anaplerotic therapy, plasma AA status improved markedly, with 65% of AAs below normal before CRRT vs. 15% after CRRT. CONCLUSIONS: In acute decompensated OAs, CRRT performed without protein supplementation, as currently recommended, significantly reduces total plasma AA concentrations and may impair restoration of anabolism. AA infusion during CRRT could help preserve or restore protein anabolism. Prospective studies are needed to assess the safety and efficacy of AA supplementation during CRRT, with or without anaplerotic therapy, in this setting.
Related
- High‐Dose L‐Serine Supplementation During Febrile Decompensation in SARS1 Deficiency: A Case Report and Review of the Literature
- APASL-ACLF without previous decompensation is immunologically distinct from EASL-CLIF-ACLF with previous decompensation
- Connexin 40 deficiency alters the temporal profile of postictal oxygen dynamics following focal seizures.
- IRE1 deficiency in myeloid cells increases atherosclerosis in apoE−/− mice
- Familial Pancreatic Cancer Associated with a Shared BRIP1 Variant: Implications for Homologous Recombination Deficiency and Targeted Therapy
BibTeX
@article{grosyeux2026amino,
title = {{Amino Acid Deficiency Secondary to Continuous Venovenous Hemofiltration in Acute Decompensation of Organic Acidemias: An Anabolic Dead End?}},
author = {Chloé Grosyeux and Noémie Cammiciotto and Elise Jeannesson and Eva Feigerlova and Valentine Villada and Camille Wicker and Michael Levy and Manuel Schiff and Apolline Imbard and David Coelho and François Feillet and Arnaud Wiedemann},
journal = {Critical Care Explorations},
year = {2026},
month = aug,
doi = {10.1097/cce.0000000000001413},
url = {https://hal.univ-lorraine.fr/hal-05752966v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Amino Acid Deficiency Secondary to Continuous Venovenous Hemofiltration in Acute Decompensation of Organic Acidemias: An Anabolic Dead End?
AU - Chloé Grosyeux
AU - Noémie Cammiciotto
AU - Elise Jeannesson
AU - Eva Feigerlova
AU - Valentine Villada
AU - Camille Wicker
AU - Michael Levy
AU - Manuel Schiff
AU - Apolline Imbard
AU - David Coelho
AU - François Feillet
AU - Arnaud Wiedemann
PY - 2026
DA - 2026/08/03
JO - Critical Care Explorations
DO - 10.1097/cce.0000000000001413
UR - https://hal.univ-lorraine.fr/hal-05752966v1
AB - OBJECTIVE: To evaluate the impact of continuous renal replacement therapy (CRRT) on plasma amino acid (AA) concentrations in patients with acute metabolic decompensation of organic acidemias (OAs), and to explore whether AA supplementation during CRRT may mitigate AA depletion. DESIGN: Multicenter retrospective observational study. SETTING: PICUs managing acute metabolic decompensations of OAs. PATIENTS OR SUBJECTS: Patients with confirmed OAs who underwent CRRT for severe acute metabolic decompensation. INTERVENTIONS: CRRT was initiated according to current guidelines in cases of severe decompensation. Standard metabolic management included high caloric intake through carbohydrates and lipids with temporary protein withdrawal (24-48 hr). In one patient, AA supplementation (2 g/kg) during CRRT combined with thiamin and citrate (anaplerotic therapy) was administered. MEASUREMENTS AND MAIN RESULTS: Plasma AA concentrations were measured before and after CRRT in nine patients with a median age of 21 days (interquartile range [IQR], 3-570 d). Quantitative variables are expressed as medians (IQR, 25th-75th). Before CRRT, 31% (95% CI, 24-39) of plasma AAs were below the normal range compared with 69% (95% CI, 59-77) after CRRT (p < 0.0001). A significant increase in lactatemia was observed following CRRT, without evidence of organ failure: median 2.2 mmol/L (IQR, 1.3-2.3) before CRRT vs. 5.3 mmol/L (IQR, 3.2-7.1) after CRRT; Hodges-Lehmann median difference +3.2 (95% CI, 0.8-5.6; p = 0.0065). In the patient receiving AA supplementation with anaplerotic therapy, plasma AA status improved markedly, with 65% of AAs below normal before CRRT vs. 15% after CRRT. CONCLUSIONS: In acute decompensated OAs, CRRT performed without protein supplementation, as currently recommended, significantly reduces total plasma AA concentrations and may impair restoration of anabolism. AA infusion during CRRT could help preserve or restore protein anabolism. Prospective studies are needed to assess the safety and efficacy of AA supplementation during CRRT, with or without anaplerotic therapy, in this setting.
SN - 2639-8028
ER -